Study evaluates the link between progesterone receptor expression and endocrine therapy outcomes in low-grade serous ovarian carcinoma, suggesting potential for tailored treatments.
Low-grade serous ovarian carcinoma (LGSOC) is characterized by relative chemoresistance and frequent hormone receptor expression. Endocrine therapy is used in selected settings; however, no biomarker is available to guide patient selection. We evaluated the association between progesterone receptor (PR) expression and endocrine therapy outcomes and its relationship with estrogen receptor (ER) levels.
No takes yet. Share an insight, caveat, or question.
Zengin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: